Endoluten
/ Khavinson-tradition extended pineal bioregulator (AEDG-related; epitalon analog)ALIAS · Endoluten · Extended pineal bioregulator · AEDG variant
Terms in this page you can click for a plain-English popup: , , , , , , , .
Tier 4. Endoluten is a Khavinson-tradition vendor preparation positioned as an extended / oral form of the AEDG (Ala-Glu-Asp-Gly) tetrapeptide marketed under the names Epitalon and Pinealon. The published primary literature on AEDG sits with the parent Epitalon / Pinealon programmes from the Saint-Petersburg Institute of Bioregulation and Gerontology; Endoluten itself is not a distinct chemical entity in PubMed-indexed primary literature.
Endoluten is described in vendor materials as an extended-release pineal bioregulator built around the Ala-Glu-Asp-Gly (AEDG) tetrapeptide that is the active principle in the Khavinson-tradition compounds Epitalon and Pinealon. The AEDG tetrapeptide has been proposed by the Khavinson group to interact with promoter regions of telomerase and circadian-related genes and to modulate pineal melatonin signalling. The molecular events underlying these effects have not been independently characterised outside the originating laboratory.
Tier 4. There is no PubMed-indexed primary literature on Endoluten as a distinct molecular entity. Inference is by claimed equivalence to the AEDG core of Epitalon and Pinealon, which carry Russian-origin preclinical and small-clinical literature from the Khavinson group.
No formal human safety database for Endoluten as a distinct preparation. The parent Epitalon Russian-language record reports tolerability in elderly cohorts; safety read-across to vendor-sold Endoluten is not supported by direct data, identity verification, or purity standards comparable to a regulated pharmaceutical preparation.
Regulatory status
- FDA status:
- Not FDA-approved
The Khavinson school (Saint-Petersburg Institute of Bioregulation and Gerontology) has published an extensive body of work on short-peptide 'bioregulators' derived from animal-tissue extracts, with a unifying claim that tissue-specific tetrapeptides (and shorter motifs) regulate gene expression and tissue-specific cell function. The corpus is Russian-origin and substantially self-cited; independent Western replication of the foundational findings has not been established.
Endoluten has a specific nomenclature issue: it is sold as a distinct product but its claimed active sequence is the same Ala-Glu-Asp-Gly (AEDG) core that is already represented in the Open Assay record under Epitalon. Vendor marketing does not always disclose this relationship. Subjects comparing Endoluten and Epitalon offerings should treat them as variant presentations of the same underlying claimed active and evaluate the published evidence at the AEDG / Epitalon level rather than expecting a separate Endoluten evidence base.